| Literature DB >> 34984431 |
Logan Stuck1,2, Aimee Claire van Haaster2, Pascalina Kapata-Chanda3, Eveline Klinkenberg1, Nathan Kapata3,4, Frank Cobelens1,2.
Abstract
BACKGROUND: Pulmonary tuberculosis infection can manifest in different states, including subclinical tuberculosis. It is commonly defined as confirmed tuberculosis without the classic symptoms (commonly, persistent cough for ≥2 weeks). This narrow definition likely poses limitations for surveillance and control measures. The aims of the current study were to characterize the clinical presentation of tuberculosis; estimate the prevalence of subclinical tuberculosis among individuals with bacteriologically confirmed tuberculosis, using various definitions; and investigate risk factors for subclinical as opposed to clinical tuberculosis in a population-based survey.Entities:
Keywords: asymptomatic; prevalence; screening; subclinical; tuberculosis
Mesh:
Year: 2022 PMID: 34984431 PMCID: PMC9477454 DOI: 10.1093/cid/ciab1050
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 20.999
Definitions of Subclinical Tuberculosis
| Definition | Criteria | Source |
|---|---|---|
| Definition 1 | No cough persisting for ≥2 wk, irrespective of other symptoms | Complement to standard screening rule for tuberculosis used in most national tuberculosis programs |
| Definition 2 | No cough, fever, night sweats, or weight loss for any duration of time | Complement to WHO screening rule for tuberculosis in people living with HIV |
Abbreviations: HIV, human immunodeficiency virus; WHO, World Health Organization.
Sample Description, Clinical Characteristics, and Prevalence, Stratified by Definitions of Subclinical Tuberculosis
| Subjects, No. (%)[ | |||||||
|---|---|---|---|---|---|---|---|
| Subclinical Tuberculosis by Definition 1 | Subclinical Tuberculosis by Definition 2 | ||||||
| Characteristics and Symptoms | Yes (n = 104) | No (n = 153) |
| Yes (n = 32) | No (n = 225) |
| Overall (n = 257) |
| Female sex | 57 (54.8) | 55 (35.9) | .004 | 16 (50.0) | 96 (42.7) | .55 | 112 (43.6) |
| Age, median (IQR), y | 41.0 (31.0–52.0) | 39.0 (30.0–51.0) | 40.0 (32.0–55.0) | 39.0 (30.0–50.0) | 39.0 (31.0–51.0) | ||
| Urban residence | 53 (51.0) | 87 (56.9) | .42 | 20 (62.5) | 120 (53.3) | .43 | 140 (54.5) |
| SES tertile | .82 | .06 | |||||
| Lowest | 22 (21.2) | 26 (17.0) | 3 (9.4) | 45 (20.0) | 48 (18.7) | ||
| Middle | 25 (24.0) | 41 (26.8) | 6 (18.8) | 60 (26.7) | 66 (25.7) | ||
| Highest | 49 (47.1) | 72 (47.1) | 22 (68.8) | 99 (44.0) | 121 (47.1) | ||
| Missing | 8 (7.7) | 14 (9.2) | 1 (3.1) | 21 (9.3) | 22 (8.6) | ||
| HIV result | .61 | .88 | |||||
| Negative | 39 (37.5) | 56 (36.6) | 11 (34.4) | 84 (37.3) | 95 (37.0) | ||
| Positive | 17 (16.3) | 19 (12.4) | 4 (12.5) | 32 (14.2) | 36 (14.0) | ||
| No test | 48 (46.2) | 78 (51.0) | 17 (53.1) | 109 (48.4) | 126 (49.0) | ||
| Symptoms | |||||||
| Cough | … | … | |||||
| None | 73 (70.2) | 0 (0) | 32 (100) | 41 (18.2) | 73 (28.4) | ||
| <2 wk | 31 (29.8) | 0 (0) | 0 (0) | 31 (13.8) | 31 (12.1) | ||
| ≥2 wk | 0 (0) | 153 (100) | 0 (0) | 153 (68.0) | 153 (59.5) | ||
| Fever | <.001 | … | |||||
| None | 79 (76.0) | 73 (47.7) | 32 (100) | 120 (53.3) | 152 (59.1) | ||
| <2 wk | 13 (12.5) | 16 (10.5) | 0 (0) | 29 (12.9) | 29 (11.3) | ||
| ≥2 wk | 12 (11.5) | 64 (41.8) | 0 (0) | 76 (33.8) | 76 (29.6) | ||
| Chest pain | <.001 | … | |||||
| None | 56 (53.8) | 34 (22.2) | 23 (71.9) | 67 (29.8) | 90 (35.0) | ||
| <2 wk | 16 (15.4) | 10 (6.5) | 1 (3.1) | 25 (11.1) | 26 (10.1) | ||
| ≥2 wk | 32 (30.8) | 109 (71.2) | 8 (25.0) | 133 (59.1) | 141 (54.9) | ||
| Night sweats | .008 | … | |||||
| None | 75 (72.1) | 91 (59.5) | 32 (100) | 134 (59.6) | 166 (64.6) | ||
| <2 wk | 10 (9.6) | 8 (5.2) | 0 (0) | 18 (8.0) | 18 (7.0) | ||
| ≥2 wk | 19 (18.3) | 54 (35.3) | 0 (0) | 73 (32.4) | 73 (28.4) | ||
| Weight loss | <.001 | … | |||||
| None | 64 (61.5) | 67 (43.8) | 32 (100) | 99 (44.0) | 131 (51.0) | ||
| <2 wk | 10 (9.6) | 5 (3.3) | 0 (0) | 15 (6.7) | 15 (5.8) | ||
| ≥2 wk | 30 (28.8) | 81 (52.9) | 0 (0) | 111 (49.3) | 111 (43.2) | ||
| Duration of longest symptom, median (IQR), wk | 2.00 (1.0–4.0) | 4.00 (2.0–8.0) | <.001 | 0 (0.0–1.3) | 4.00 (2.0–8.0) | <.001 | 4.00 (2.0–8.0) |
| Duration of longest symptom, excluding cough, median (IQR), wk | 2.00 (1.0–4.0) | 4.00 (2.0–8.0) | <.001 | 0 (0.0–1.3) | 4.00 (2.0–8.0) | <.001 | 3.00 (1.0–6.0) |
| Subclinical tuberculosis: definition 1 | 104 (100) | 0 (0) | <.001 | 32 (100) | 72 (32.0) | <.001 | 104 (40.5) |
| Subclinical tuberculosis: definition 2 | 32 (30.8) | 0 (0) | <.001 | 32 (100) | 0 (0) | <.001 | 32 (12.5) |
Symptoms which defined comparison groups were not included in significance testing.
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; SES, socioeconomic status.
Unless otherwise indicated, data represent no. (%) of subjects, with percentages based on column totals provided in column headings.
Figure 1.Upset chart displaying symptom combinations (of any duration) by frequency for subjects. “Asymptomatic” refers to individuals without sweats, fever, weight loss, chest pain, or cough. Intersection size refers to the number of subjects with the indicated combination of symptoms; set size, the number experiencing each individual symptom.
Figure 2.Euler diagram displaying share (numbers) of subjects meeting various definitions for subclinical tuberculosis. Definition 1: no cough persisting for ≥2 weeks, irrespective of other symptoms. subclinical tuberculosis; definition 2: no cough, fever, night sweats, or weight loss for any duration of time, irrespective of chest pain.
Figure 3.Proportion of subjects with subclinical tuberculosis (defined according to definition 1) with chest pain, fever, night sweats, or weight loss, disaggregated by duration of symptoms.
Regression Table With Odds Ratios and Confidence Intervals for Unadjusted Associations, the Full Adjusted Model, and the Final Reduced Model for Both Definitions of Subclinical Tuberculosis
| Odds Ratio (95% CI)[ | ||||
|---|---|---|---|---|
| Subclinical Tuberculosis Definition 1 | Subclinical Tuberculosis Definition 2 | |||
| Subject Characteristics | Unadjusted | Final Adjusted | Unadjusted | Final Adjusted |
| Sex | ||||
| Female | Reference | Reference | Reference | … |
| Male | 0.46 (.28–.77) | 0.46 (.28–.77) | 0.74 (.35–1.57) | … |
| Age group, y | ||||
| 15–24 | Reference | … | Reference | … |
| 25–35 | 0.75 (.31–1.8) | … | 1.12 (.33–4.45) | … |
| 35–44 | 0.59 (.25–1.43) | … | 0.54 (.13–2.35) | … |
| 45–54 | 1.46 (.58–3.71) | … | 0.87 (.21–3.77) | … |
| 55–64 | 1.34 (.44–4.12) | … | 2.11 (.49–9.65) | … |
| ≥65 | 0.5 (.17–1.4) | … | 1 (.22–4.63) | … |
| Residence | ||||
| Rural | Reference | … | Reference | … |
| Urban | 0.79 (.48–1.3) | … | 1.46 (.69–3.21) | … |
| SES tertile | ||||
| Lowest | Reference | … | Reference | Reference |
| Middle | 0.72 (.34–1.53) | … | 1.5 (.37–7.41) | 1.50 (.37–7.41) |
| Highest | 0.8 (.41–1.59) | … | 3.33 (1.08–14.59) | 3.33 (1.08–14.59) |
| Missing | 0.68 (.23–1.88) | … | 0.71 (.03–5.96) | 0.71 (.03–5.96) |
| HIV result | ||||
| Negative | Reference | … | Reference | … |
| Positive | 1.28 (.59–2.79) | … | 0.95 (.25–3.02) | … |
| No test | 0.88 (.51–1.53) | … | 1.19 (.54–2.75) | … |
| Constant | … | 1.04 (.72–1.50) | … | 0.07 (.02–.18) |
| Observations, no. | … | 257 | … | 257 |
| Log likelihood | … | −168.96 | … | −92.77 |
| AIC | … | 341.91 | … | 193.53 |
Abbreviations: AIC, Akaike information criterion; CI, confidence interval; HIV, human immunodeficiency virus; SES, socioeconomic status.
Data represent odds ratios (95% CIs) except in the bottom 3 rows.